Valvular Disease in Marfan Syndrome: Surgical Considerations and Management

  • Ryan P. Plichta
  • Donald D. Glower
  • G. Chad HughesEmail author
Valvular Heart Disease (TL Kiefer, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Valvular Heart Disease


Purpose of Review

Detail the current strategies for the management of valve dysfunction in Marfan syndrome (MFS), understand the limitations of surgical interventions, and delineate the likely direction of future innovations.

Recent Findings

Significant advances in both medical and surgical management of MFS have been made over the last 50 years. This has resulted in improved overall outcomes. As MFS patients age, new clinical challenges that were once rare have emerged and can require complex care strategies. Medical management has seen advances and focuses on anti-impulse and molecular-based pharmacotherapy, along with close monitoring with serial imaging to minimize acute aortic dissection risk by selecting appropriate timing of prophylactic surgical intervention with increasing aortic dimensions. Ongoing trials are evaluating other potential drug therapies with the ultimate goal of targeted treatment.


Over the last 50 years, significant advances have been made in the understanding and management of MFS. A move to prophylactic surgery for aortopathy and valve disease has progressed from a valve replacement to a valve-sparing strategy in many cases. However, the durability of these repairs is variable and the possibility of reintervention looms.


Marfan syndrome Valvular disease Surgical management Connective tissue disorder 


Compliance with Ethical Standards

Conflict of Interest

Ryan P. Plichta, Donald D. Glower, and G. Chad Hughes declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.


Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Dean JC. Marfan syndrome: clinical diagnosis and management. Eur J Hum Genet. 2007;15(7):724–33. Scholar
  2. 2.
    Stuart AG, Williams A. Marfan’s syndrome and the heart. Arch Dis Child. 2007;92(4):351–6. Scholar
  3. 3.
    Murdoch JL, Walker BA, Halpern BL, Kuzma JW, McKusick VA. Life expectancy and causes of death in the Marfan syndrome. N Engl J Med. 1972;286(15):804–8. Scholar
  4. 4.
    Coselli JS, Volguina IV, LeMaire SA, Sundt TM, Connolly HM, Stephens EH, et al. Early and 1-year outcomes of aortic root surgery in patients with Marfan syndrome: a prospective, multicenter, comparative study. J Thorac Cardiovasc Surg. 2014;147(6):1758–66, 67 e1–4. Scholar
  5. 5.
    De Paulis R, De Matteis GM, Nardi P, Scaffa R, Colella DF, Chiarello L. A new aortic Dacron conduit for surgical treatment of aortic root pathology. Ital Heart J. 2000;1(7):457–63.PubMedGoogle Scholar
  6. 6.
    David TE, Feindel CM. An aortic valve-sparing operation for patients with aortic incompetence and aneurysm of the ascending aorta. J Thorac Cardiovasc Surg. 1992;103(4):617–21 discussion 22.PubMedGoogle Scholar
  7. 7.
    Benedetto U, Melina G, Takkenberg JJ, Roscitano A, Angeloni E, Sinatra R. Surgical management of aortic root disease in Marfan syndrome: a systematic review and meta-analysis. Heart. 2011;97(12):955–8. Scholar
  8. 8.
    Dietz HC, Cutting GR, Pyeritz RE, Maslen CL, Sakai LY, Corson GM, et al. Marfan syndrome caused by a recurrent de novo missense mutation in the fibrillin gene. Nature. 1991;352(6333):337–9. Scholar
  9. 9.
    Hiratzka LF, Bakris GL, Beckman JA, Bersin RM, Carr VF, Casey DE Jr, et al. 2010 ACCF/AHA/AATS/ACR/ASA/SCA/SCAI/SIR/STS/SVM guidelines for the diagnosis and management of patients with Thoracic Aortic Disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Association for Thoracic Surgery, American College of Radiology, American Stroke Association, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of Thoracic Surgeons, and Society for Vascular Medicine. Circulation. 2010;121(13):e266–369. Scholar
  10. 10.
    Shores J, Berger KR, Murphy EA, Pyeritz RE. Progression of aortic dilatation and the benefit of long-term beta-adrenergic blockade in Marfan’s syndrome. N Engl J Med. 1994;330(19):1335–41. Scholar
  11. 11.
    Gersony DR, McClaughlin MA, Jin Z, Gersony WM. The effect of beta-blocker therapy on clinical outcome in patients with Marfan’s syndrome: a meta-analysis. Int J Cardiol. 2007;114(3):303–8. Scholar
  12. 12.
    Gao L, Mao Q, Wen D, Zhang L, Zhou X, Hui R. The effect of beta-blocker therapy on progressive aortic dilatation in children and adolescents with Marfan’s syndrome: a meta-analysis. Acta Paediatr. 2011;100(9):e101–5. Scholar
  13. 13.
    Neptune ER, Frischmeyer PA, Arking DE, Myers L, Bunton TE, Gayraud B, et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet. 2003;33(3):407–11. Scholar
  14. 14.
    Habashi JP, Judge DP, Holm TM, Cohn RD, Loeys BL, Cooper TK, et al. Losartan, an AT1 antagonist, prevents aortic aneurysm in a mouse model of Marfan syndrome. Science. 2006;312(5770):117–21. Scholar
  15. 15.
    Lacro RV, Dietz HC, Sleeper LA, Yetman AT, Bradley TJ, Colan SD, et al. Atenolol versus losartan in children and young adults with Marfan’s syndrome. N Engl J Med. 2014;371(22):2061–71. Scholar
  16. 16.
    Groenink M, den Hartog AW, Franken R, Radonic T, de Waard V, Timmermans J, et al. Losartan reduces aortic dilatation rate in adults with Marfan syndrome: a randomized controlled trial. Eur Heart J. 2013;34(45):3491–500. Scholar
  17. 17.
    Baumgartner H, Bonhoeffer P, De Groot NM, de Haan F, Deanfield JE, Galie N, et al. ESC guidelines for the management of grown-up congenital heart disease (new version 2010). Eur Heart J. 2010;31(23):2915–57. Scholar
  18. 18.
    Silverman DI, Burton KJ, Gray J, Bosner MS, Kouchoukos NT, Roman MJ, et al. Life expectancy in the Marfan syndrome. Am J Cardiol. 1995;75(2):157–60.CrossRefGoogle Scholar
  19. 19.
    Bentall H, De Bono A. A technique for complete replacement of the ascending aorta. Thorax. 1968;23(4):338–9.CrossRefGoogle Scholar
  20. 20.
    Kouchoukos NT, Wareing TH, Murphy SF, Perrillo JB. Sixteen-year experience with aortic root replacement. Results of 172 operations. Ann Surg. 1991;214(3):308–18 discussion 18-20.CrossRefGoogle Scholar
  21. 21.
    Cameron DE, Alejo DE, Patel ND, Nwakanma LU, Weiss ES, Vricella LA, et al. Aortic root replacement in 372 Marfan patients: evolution of operative repair over 30 years. Ann Thorac Surg. 2009;87(5):1344–9 discussion 9-50.CrossRefGoogle Scholar
  22. 22.
    Gott VL, Greene PS, Alejo DE, Cameron DE, Naftel DC, Miller DC, et al. Replacement of the aortic root in patients with Marfan’s syndrome. N Engl J Med. 1999;340(17):1307–13. Scholar
  23. 23.
    Sarsam MA, Yacoub M. Remodeling of the aortic valve anulus. J Thorac Cardiovasc Surg. 1993;105(3):435–8.PubMedGoogle Scholar
  24. 24.
    Fleischer KJ, Nousari HC, Anhalt GJ, Stone CD, Laschinger JC. Immunohistochemical abnormalities of fibrillin in cardiovascular tissues in Marfan’s syndrome. Ann Thorac Surg. 1997;63(4):1012–7.CrossRefGoogle Scholar
  25. 25.
    •• David TE, David CM, Manlhiot C, Colman J, Crean AM, Bradley T. Outcomes of aortic valve-sparing operations in Marfan syndrome. J Am Coll Cardiol. 2015;66(13):1445–53. This study examined the long-term outcomes of valve-sparing operations in patients with MFS. CrossRefPubMedGoogle Scholar
  26. 26.
    Lansac E, Di Centa I, Sleilaty G, Lejeune S, Berrebi A, Zacek P, et al. Remodeling root repair with an external aortic ring annuloplasty. J Thorac Cardiovasc Surg. 2017;153(5):1033–42. Scholar
  27. 27.
    Coselli JS. It’s time to get to the root of things. J Thorac Cardiovasc Surg. 2016;151(2):291–3. Scholar
  28. 28.
    Svensson LG, Blackstone EH, Alsalihi M, Batizy LH, Roselli EE, McCullough R, et al. Midterm results of David reimplantation in patients with connective tissue disorder. Ann Thorac Surg. 2013;95(2):555–62. Scholar
  29. 29.
    De Paulis R, Scaffa R, Nardella S, Maselli D, Weltert L, Bertoldo F, et al. Use of the Valsalva graft and long-term follow-up. J Thorac Cardiovasc Surg. 2010;140(6 Suppl):S23–7; discussion S45–51. Scholar
  30. 30.
    • Flynn CD, Tian DH, Wilson-Smith A, David T, Matalanis G, Misfeld M, et al. Systematic review and meta-analysis of surgical outcomes in Marfan patients undergoing aortic root surgery by composite-valve graft or valve sparing root replacement. Ann Cardiothorac Surg. 2017;6(6):570–81. This is a review and meta-analysis of MFS patients undergoing aortic root replacement surgery and compared valve-sparing and valve replacement strategies.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Boodhwani M, de Kerchove L, Glineur D, Poncelet A, Rubay J, Astarci P, et al. Repair-oriented classification of aortic insufficiency: impact on surgical techniques and clinical outcomes. J Thorac Cardiovasc Surg. 2009;137(2):286–94. Scholar
  32. 32.
    Mazzitelli D, Fischlein T, Rankin JS, Choi YH, Stamm C, Pfeiffer S, et al. Geometric ring annuloplasty as an adjunct to aortic valve repair: clinical investigation of the HAART 300 device. Eur J Cardiothorac Surg. 2016;49(3):987–93. Scholar
  33. 33.
    Price J, Magruder JT, Young A, Grimm JC, Patel ND, Alejo D, et al. Long-term outcomes of aortic root operations for Marfan syndrome: a comparison of Bentall versus aortic valve-sparing procedures. J Thorac Cardiovasc Surg. 2016;151(2):330–6. Scholar
  34. 34.
    Puskas J, Gerdisch M, Nichols D, Quinn R, Anderson C, Rhenman B, et al. Reduced anticoagulation after mechanical aortic valve replacement: interim results from the prospective randomized on-X valve anticoagulation clinical trial randomized Food and Drug Administration investigational device exemption trial. J Thorac Cardiovasc Surg. 2014;147(4):1202–10; discussion 10-1. Scholar
  35. 35.
    Marlow N, Gregg JE, Qureshi SA. Mitral valve disease in Marfan’s syndrome. Arch Dis Child. 1987;62(9):960–2.CrossRefGoogle Scholar
  36. 36.
    Pyeritz RE, Wappel MA. Mitral valve dysfunction in the Marfan syndrome. Clinical and echocardiographic study of prevalence and natural history. Am J Med. 1983;74(5):797–807.CrossRefGoogle Scholar
  37. 37.
    Rybczynski M, Treede H, Sheikhzadeh S, Groene EF, Bernhardt AM, Hillebrand M, et al. Predictors of outcome of mitral valve prolapse in patients with the Marfan syndrome. Am J Cardiol. 2011;107(2):268–74. Scholar
  38. 38.
    Nishimura RA, Otto CM, Bonow RO, Carabello BA, Erwin JP 3rd, Guyton RA, et al. 2014 AHA/ACC guideline for the management of patients with valvular heart disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(23):2440–92. Scholar
  39. 39.
    Gillinov AM, Cosgrove DM, Blackstone EH, Diaz R, Arnold JH, Lytle BW, et al. Durability of mitral valve repair for degenerative disease. J Thorac Cardiovasc Surg. 1998;116(5):734–43. Scholar
  40. 40.
    Bhudia SK, Troughton R, Lam BK, Rajeswaran J, Mills WR, Gillinov AM, et al. Mitral valve surgery in the adult Marfan syndrome patient. Ann Thorac Surg. 2006;81(3):843–8. Scholar
  41. 41.
    David TE, Ivanov J, Armstrong S, Christie D, Rakowski H. A comparison of outcomes of mitral valve repair for degenerative disease with posterior, anterior, and bileaflet prolapse. J Thorac Cardiovasc Surg. 2005;130(5):1242–9. Scholar
  42. 42.
    Javadikasgari H, Mihaljevic T, Suri RM, Svensson LG, Navia JL, Wang RZ, et al. Simple versus complex degenerative mitral valve disease. J Thorac Cardiovasc Surg. 2018;156(1):122–9 e16. Scholar
  43. 43.
    Helder MR, Schaff HV, Dearani JA, Li Z, Stulak JM, Suri RM, et al. Management of mitral regurgitation in Marfan syndrome: outcomes of valve repair versus replacement and comparison with myxomatous mitral valve disease. J Thorac Cardiovasc Surg. 2014;148(3):1020–4; discussion 4. Scholar
  44. 44.
    Kunkala MR, Schaff HV, Li Z, Volguina I, Dietz HC, LeMaire SA, et al. Mitral valve disease in patients with Marfan syndrome undergoing aortic root replacement. Circulation. 2013;128(11 Suppl 1):S243–7. Scholar
  45. 45.
    • Javadikasgari H, Roselli EE, Aftab M, Suri RM, Desai MY, Khosravi M, et al. Combined aortic root replacement and mitral valve surgery: the quest to preserve both valves. J Thorac Cardiovasc Surg. 2017;153(5):1023–30 e1. This study exmanines the pathology and surgical outcomes of patients with combined aortic root and mitral valve disease. CrossRefPubMedGoogle Scholar
  46. 46.
    David TE, Armstrong S, Maganti M, Ihlberg L. Clinical outcomes of combined aortic root replacement with mitral valve surgery. J Thorac Cardiovasc Surg. 2008;136(1):82–7. Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Ryan P. Plichta
    • 1
  • Donald D. Glower
    • 1
  • G. Chad Hughes
    • 1
    Email author
  1. 1.Division of Thoracic and Cardiovascular SurgeryDuke University Medical CenterDurhamUSA

Personalised recommendations